Comparative effectiveness of dexamethasone in treatment of hospitalized COVID-19 patients in the United States during the first year of the pandemic: Findings from the National COVID Cohort Collaborative (N3C) data repository.

3.2.2 Effect of dexamethasone Rates of in-hospital death or referral to hospice were lower in the dexamethasone-treated group compared to the non-dexamethasone-treated matched control group for those receiving remdesivir (OR = 0.74, 95% CI: 0.53 to 1.02), those not receiving remdesivir (OR = 0.77, 95% CI: 0.62 to 0.95), and both remdesivir and non-remdesivir treated groups combined (OR = 0.77, 95% CI: 0.64 to 0.91), although the effect in the smaller remdesivir stratum was only borderline significant.

also in 11,409 other papers